Chiara Demartini
Overview
Explore the profile of Chiara Demartini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greco R, Francavilla M, Facchetti S, Demartini C, Zanaboni A, Antonangeli M, et al.
J Headache Pain
. 2024 Oct;
25(1):184.
PMID: 39455939
Background: In addition to its critical role in neurogenesis, brain-derived neurotrophic factor (BDNF) modulates pain and depressive behaviors. Methods: In a translational perspective, we tested the anti-migraine activity of highly...
2.
Greco R, Bighiani F, Demartini C, Zanaboni A, Francavilla M, Facchetti S, et al.
J Headache Pain
. 2024 Oct;
25(1):179.
PMID: 39407118
No abstract available.
3.
Greco R, Bighiani F, Demartini C, Zanaboni A, Francavilla M, Facchetti S, et al.
J Headache Pain
. 2024 Aug;
25(1):138.
PMID: 39187749
Background: miR-155 is involved in the generation and maintenance of inflammation and pain, endothelial function and immune system homeostasis, all functions that are relevant for migraine. The present study aims...
4.
Francavilla M, Facchetti S, Demartini C, Zanaboni A, Amoroso C, Bottiroli S, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928361
Migraine is a common and debilitating neurological disorder characterized by the recurrent attack of pulsating headaches typically localized on one side of the head associated with other disabling symptoms, such...
5.
Greco R, Demartini C, Francavilla M, Zanaboni A, Facchetti S, Palmisani M, et al.
Cells
. 2024 May;
13(10).
PMID: 38786051
The inhibition of endocannabinoid hydrolysis by enzymatic inhibitors may interfere with mechanisms underlying migraine-related pain. The dual FAAH/MAGL inhibitor AKU-005 shows potent inhibitory activity in vitro. Here, we assessed the...
6.
Demartini C, Greco R, Zanaboni A, Francavilla M, Facchetti S, Tassorelli C
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004491
Cannabinoids are proposed for alleviating neuropathic pain, but their use is limited by cannabimimetic side effects. The inhibition of the fatty acid amide hydrolase (FAAH), the degrading enzyme of the...
7.
Greco R, Francavilla M, Demartini C, Zanaboni A, Facchetti S, Palmisani M, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373250
Increased anandamide levels via fatty acid amide hydrolase (FAAH) inhibition can decrease the pronociceptive responses and inflammatory mediators in animal models of migraine. Here, we profile the pharmacological activity of...
8.
Greco R, Francavilla M, Demartini C, Zanaboni A, Sodergren M, Facchetti S, et al.
J Headache Pain
. 2023 Jun;
24(1):67.
PMID: 37277720
No abstract available.
9.
Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine
Greco R, Francavilla M, Demartini C, Zanaboni A, Sodergren M, Facchetti S, et al.
J Headache Pain
. 2023 May;
24(1):48.
PMID: 37138206
Cannabidiol (CBD) is the main pharmacologically active phytocannabinoid. CBD exerts an analgesic effect in several pain models, does not have side effects and has low toxicity. The data about CBD...
10.
Demartini C, Francavilla M, Zanaboni A, Facchetti S, De Icco R, Martinelli D, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982428
In recent years, numerous efforts have been made to identify reliable biomarkers useful in migraine diagnosis and progression or associated with the response to a specific treatment. The purpose of...